Literature DB >> 20682796

Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma.

Emilia Albesiano1, Meghan Davis, Alfred P See, James E Han, Michael Lim, Drew M Pardoll, Young Kim.   

Abstract

Paracrine cross-talk between tumor cells and immune cells within the tumor microenvironment underlies local mechanisms of immune evasion. Signal transducer and activator of transcription 3 (STAT3), which is constitutively activated in diverse cancer types, is a key regulator of cytokine and chemokine expression in murine tumors, resulting in suppression of both innate and adaptive antitumor immunity. However, the immunologic effects of STAT3 activation in human cancers have not been studied in detail. To investigate how STAT3 activity in human head and neck squamous cell carcinoma (HNSCC) might alter the tumor microenvironment to enable immune escape, we used small interfering RNA and small-molecule inhibitors to suppress STAT3 activity. STAT3 inhibition in multiple primary and established human squamous carcinoma lines resulted in enhanced expression and secretion of both proinflammatory cytokines and chemokines. Although conditioned medium containing supernatants from human HNSCC inhibited lipopolysaccharide-induced dendritic cell activation in vitro, supernatants from STAT3-silenced tumor cells reversed this immune evasion mechanism. Moreover, supernatants from STAT3-silenced tumor cells were able to stimulate the migratory behavior of lymphocytes from human peripheral blood in vitro. These results show the importance of STAT3 activation in regulating the immunomodulatory mediators by human tumors and further validate STAT3 as a promising target for therapeutic intervention. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682796      PMCID: PMC2922407          DOI: 10.1158/0008-5472.CAN-09-4058

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.

Authors:  I Narvaiza; G Mazzolini; M Barajas; M Duarte; M Zaratiegui; C Qian; I Melero; J Prieto
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

2.  Validating Stat3 in cancer therapy.

Authors:  James E Darnell
Journal:  Nat Med       Date:  2005-06       Impact factor: 53.440

3.  In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.

Authors:  Sichuan Xi; William E Gooding; Jennifer Rubin Grandis
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

4.  Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.

Authors:  Timothy J Harris; Joseph F Grosso; Hung-Rong Yen; Hong Xin; Marcin Kortylewski; Emilia Albesiano; Edward L Hipkiss; Derese Getnet; Monica V Goldberg; Charles H Maris; Franck Housseau; Hua Yu; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

5.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.

Authors:  Thomas Welte; Samuel S M Zhang; Tian Wang; Zhiyuan Zhang; David G T Hesslein; Zhinan Yin; Arihiro Kano; Yoshiki Iwamoto; En Li; Joseph E Craft; Alfred L M Bothwell; Erol Fikrig; Pandelakis A Koni; Richard A Flavell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

6.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Authors:  Marcin Kortylewski; Hong Xin; Maciej Kujawski; Heehyoung Lee; Yong Liu; Timothy Harris; Charles Drake; Drew Pardoll; Hua Yu
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

7.  TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma.

Authors:  M Enderlin; E V Kleinmann; S Struyf; C Buracchi; A Vecchi; R Kinscherf; F Kiessling; S Paschek; S Sozzani; J Rommelaere; J J Cornelis; J Van Damme; C Dinsart
Journal:  Cancer Gene Ther       Date:  2008-08-01       Impact factor: 5.987

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  Small molecule tyrosine kinase inhibitors in pancreatic cancer.

Authors:  Sachin Gupta; Bassel F El-Rayes
Journal:  Biologics       Date:  2008-12

10.  Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.

Authors:  D D Taub; A R Lloyd; K Conlon; J M Wang; J R Ortaldo; A Harada; K Matsushima; D J Kelvin; J J Oppenheim
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  13 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 2.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

Review 3.  Head and Neck Carcinoma Immunotherapy: Facts and Hopes.

Authors:  Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

4.  Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma.

Authors:  Lin-Lin Bu; Guang-Tao Yu; Wei-Wei Deng; Liang Mao; Jian-Feng Liu; Si-Rui Ma; Teng-Fei Fan; Bradford Hall; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

5.  The role of STAT3 activation in modulating the immune microenvironment of GBM.

Authors:  Alfred P See; James E Han; Jillian Phallen; Zev Binder; Gary Gallia; Fan Pan; Dilini Jinasena; Christopher Jackson; Zineb Belcaid; Sung Jin Jeong; Chelsea Gottschalk; Jing Zeng; Jacob Ruzevick; Sarah Nicholas; Young Kim; Emilia Albesiano; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

6.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.

Authors:  David Vasquez-Dunddel; Fan Pan; Qi Zeng; Mikhail Gorbounov; Emilia Albesiano; Juan Fu; Richard L Blosser; Ada J Tam; Tullia Bruno; Hao Zhang; Drew Pardoll; Young Kim
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 7.  The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

Authors:  Jessica L Geiger; Jennifer R Grandis; Julie E Bauman
Journal:  Oral Oncol       Date:  2015-12-28       Impact factor: 5.337

8.  Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.

Authors:  O Bucur; A L Stancu; R Khosravi-Far; A Almasan
Journal:  Cell Death Dis       Date:  2012-02-02       Impact factor: 8.469

9.  Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice.

Authors:  Paulina Pathria; Dagmar Gotthardt; Michaela Prchal-Murphy; Eva-Maria Putz; Martin Holcmann; Michaela Schlederer; Beatrice Grabner; Ilija Crncec; Jasmin Svinka; Monica Musteanu; Thomas Hoffmann; Martin Filipits; Walter Berger; Valeria Poli; Lukas Kenner; Martin Bilban; Emilio Casanova; Mathias Müller; Birgit Strobl; Editha Bayer; Thomas Mohr; Veronika Sexl; Robert Eferl
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

10.  Autologous reconstitution of human cancer and immune system in vivo.

Authors:  Juan Fu; Rupashree Sen; David L Masica; Rachel Karchin; Drew Pardoll; Vonn Walter; D Neil Hayes; Christine H Chung; Young J Kim
Journal:  Oncotarget       Date:  2017-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.